Skip to main content

Year: 2025

Westport Announces Director Retirement

VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport”) (TSX:WPRT / Nasdaq:WPRT), announces that Brenda Eprile has retired from Westport’s Board of Directors (the “Board”), effective January 6, 2025. The Board is currently evaluating alternatives with respect to the appointment of an independent director to fill the vacancy. “On behalf of the entire Board of Directors, I would like to express our deepest gratitude to Brenda for her exceptional leadership and unwavering dedication throughout her 11 year tenure,” said Dan Hancock, Westport Fuel Systems Board Chair. “Brenda has been an invaluable part of our team, and we wish her well in her next chapter.”  About Westport Fuel Systems At Westport Fuel Systems, we are driving innovation to power a cleaner tomorrow. We are a leading...

Continue reading

Comstock Releases Shareholder Letter

VIRGINIA CITY, Nev., Jan. 13, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE American: LODE) (“Comstock” and the “Company”) today announced that its executive chairman and chief executive officer issued the following letter to Comstock’s shareholders: Dear Shareholders: On behalf of our Board of Directors, Executive Officers and the entire team, we thank you for supporting our bold and strategic transformation into an innovator and integrator of commercially ready technologies. In 2021, we set our sights on this ambitious undertaking and your support has been integral as we invested in technologies, together with the resulting systems and supply chains, that are now positioned to lead the world in enabling energy independence, and potentially energy dominance. We understand the magnitude of what we are undertaking, and we could never...

Continue reading

First Atlantic Nickel Closes Acquisition of RPM South Claims at the Atlantic Nickel Project

VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) — First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) (“First Atlantic” or the “Company”) advises that it has closed the previously announced asset purchase agreement (the “Purchase Agreement”) to acquire a 100% interest in and to mining licence 038152M, consisting of 12 mineral claims located in central Newfoundland, known as the the RPM South claims (the “Claims”). The Claims are situated immediately south of the recent discovery at the RPM Zone (See Figure 1), which is part of the 30 kilometer nickel trend within the Atlantic Nickel project (the “Atlantic Nickel Project” or the “Project”) in Newfoundland. Future drill programs will aim to test for mineralization in all directions, including at...

Continue reading

Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD pre-filled syringe (PFS) submission completed; launch expected by mid-2025 Libtayo® exceeded $1 billion in 2024 annual net sales, and becomes the first and only immunotherapy to show a statistically significant clinical benefit as adjuvant therapy in high-risk cutaneous squamous cell carcinoma (CSCC) Linvoseltamab Biologics License Application (BLA) resubmitted following resolution of third-party manufacturing issues; launch anticipated mid-2025 Approximately 40...

Continue reading

Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo Libtayo is the first and only immunotherapy to show a statistically significant and clinically meaningful benefit in high-risk CSCC in the adjuvant setting; a recent Phase 3 trial with Keytruda® failed in the same setting1  Libtayo is standard of care for certain patients with advanced CSCC TARRYTOWN, N.Y., Jan. 13, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo® (cemiplimab) led to a statistically significant and clinically meaningful improvement in the primary endpoint of...

Continue reading

Invitation to HMS Networks’ fourth quarter conference call 2024

HMS Networks AB (publ) will release its fourth quarter report of 2024 on Tuesday January 28, 2025, at approximately 07.30 AM CET. On the same day, at 09.00 AM CET, President and CEO Staffan Dahlström and CFO Joakim Nideborn present the report in a conference call for press and analysts. The presentation is in English and can be followed live via telephone or web. Slides used in the presentation will be made available on HMS’ website prior to the telephone conference. If you wish to participate via webcast, please use the link below. Link to webcast If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. Link to teleconference The presentation and recording of...

Continue reading

Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery

The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project Extensively expanded database effort is designed to dramatically accelerate discovery of new genetics-based drug targets and therapies, while also empowering the future of healthcare analytics and healthcare management Regeneron investing $119.5 million in Truveta’s Series C Financing Round TARRYTOWN, N.Y., Jan. 13, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic collaboration with Truveta, Inc. and its collective of U.S. health...

Continue reading

First Quantum Provides Notice of Fourth Quarter and Year-End 2024 Results

TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) will release fourth quarter and year-end 2024 financial and operating results on Tuesday, February 11, 2025 after the close of the Toronto Stock Exchange. The Company will host a conference call and webcast to discuss the results on Wednesday, February 12, 2025 at 9:00 am (ET). In addition, the Company will release 2024 preliminary production and three-year guidance on Wednesday, January 15, 2025 after the close of the Toronto Stock Exchange. Conference call and webcast details:Toll-free North America: 1-844-763-8274Toll-free International: +1-647-484-8814Webcast: Direct link or on our website A replay of the webcast will be available on the First Quantum website. For further information, visit our website at www.first-quantum.com...

Continue reading

Brunswick Corporation Schedules 2024 Fourth Quarter & Full Year Earnings Conference Call

METTAWA, Ill., Jan. 13, 2025 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its 2024 fourth quarter and full year financial results on Thursday, January 30, 2025 before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company’s website at https://ir.brunswick.com.  The results will also be available on the SEC’s website with the Form 8-K filing of the release at http://goo.gl/wJQN1.  The Company will hold a conference call at 10 a.m. CST/ 11 a.m. EST, Thursday, January 30, 2025, hosted by David M. Foulkes, chief executive officer, Ryan M. Gwillim, executive vice president, chief financial officer, and chief strategy officer, and Neha Clark, senior vice president, enterprise finance.  A copy of the presentation to be used on this...

Continue reading

Armada Hoffler Completes Full-Floor Office Lease at Town Center of Virginia Beach

Trader Interactive to occupy 12,000 square feet following transaction that underscores significant office activity at mixed-use district VIRGINIA BEACH, Va., Jan. 13, 2025 (GLOBE NEWSWIRE) — Armada Hoffler (NYSE: AHH) closed out a momentous year of office leasing activity at Town Center of Virginia Beach with the completion of a lease with Trader Interactive. Virginia Beach-based Trader Interactive leased a full 12,000-square-foot floor at Armada Hoffler’s flagship mixed-use development. Armada Hoffler’s lease with Trader Interactive established a new benchmark for office rent per square foot at Town Center of Virginia Beach. Lease terms were not disclosed. Trader Interactive is set to occupy the top floor of the 222 Central Ave. building, which was previously occupied by Armada Hoffler. To meet the significant demand for office...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.